Sign in to view content

Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2026

Related

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Risk of Diabetic Retinopathy Disease Progression and Hemorrhagic Outcomes Following Stroke
Katherine E. Talcott
Updates from the Field
2026
Port Delivery System with Ranibizumab PDS for Continuous Treatment in DME and DR Additional Results from the Phase 3 Pagoda and Pavilion Trials
Dennis M. Marcus, MD
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more